Egypt Diabetes Drugs Market

Egypt Diabetes Drugs Market Outlook 2031

• The industry in Egypt was valued at US$ 482.8 Mn in 2022
• It is projected to grow at a CAGR of 8.0% from 2023 to 2031 and reach more than US$ 993.0 Mn by the end of 2031

Analysts’ Viewpoint

Increase in incidence of diabetes is a key factor augmenting the Egypt diabetes drugs market size. Type 1 and type 2 diabetes have become a major health concern in Egypt, and this trend is expected to continue in the near future. Rise in investments in R&D and promising pipeline of diabetes drugs are also fueling the Egypt diabetes drugs market development.

Government initiatives to address the diabetes epidemic, including subsidizing essential diabetes medications, promoting awareness campaigns, and improving healthcare infrastructure, are likely to boost the diabetes drugs market value in the near future. Local and multinational pharmaceutical companies are introducing new medications and adopting innovative treatment options. In line with the latest Egypt diabetes drugs market trends, they are also investing in technological advancements in drug delivery systems to strengthen their industry position.

Market Introduction

Diabetes drugs, also known as antidiabetic medications or hypoglycemic agents, are pharmaceutical substances used to manage and control blood sugar levels in individuals with diabetes. Diabetes is a chronic medical condition characterized by elevated blood glucose (sugar) levels. Effective management of these levels is essential in preventing complications associated with the disease. There are various classes of diabetes drugs, each with a different mechanism of action and intended for specific types and stages of diabetes.

The Egypt diabetes drugs market encompasses a wide range of pharmaceuticals designed to manage and control blood sugar levels in individuals with diabetes, catering to both type 1 and type 2 diabetes. Key therapies include Glucagon-like Peptide-1 (GLP-1) Agonists, Dipeptidyl-peptidase-4 (DPP-4) Inhibitors, Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors, and insulin.

Changes in lifestyle and increase in aging population are prominent factors boosting the diabetes market demand in Egypt. Market dynamics are also influenced by factors such as government initiatives, strong healthcare infrastructure, advancements in drug delivery systems, and introduction of innovative treatment options.

Rise in Prevalence of Diabetes Augmenting Market Progress

The data from the International Diabetes Federation (IDF) regarding Egypt's high prevalence of diabetes is a cause for concern. Dietary habits are playing a significant role in incidence of diabetes, as Egyptians are increasingly consuming processed foods, sugary drinks, and red meat, which are often high in saturated fats and calories. This type of diet can lead to weight gain and insulin resistance, both of which are risk factors for diabetes.

Sedentary lifestyle has become more common in Egypt, with several individuals spending long hours sitting at work or school. Physical inactivity is known to increase the risk of developing type 2 diabetes. Obesity is a major risk factor for diabetes, and Egypt has one of the highest obesity rates in the world. The combination of poor dietary choices and sedentary behaviors has contributed to an alarming rise in obesity rate in the country.

Growth in prevalence of diabetes in Egypt directly impacts market statistics. Rise in number of people diagnosed with diabetes is driving the demand for medications to manage the condition. This surge in demand is encouraging pharmaceutical companies to develop and offer a variety of drugs to cater to the needs of this expanding patient population.

Public health authorities in Egypt are implementing public awareness campaigns, educational initiatives, and policies that promote healthier eating habits and physical activities to mitigate the growing burden of diabetes in the country.

Surge in geriatric population is also creating lucrative Egypt diabetes drugs market opportunities for industry players. This elderly population is more susceptible to developing diabetes. According to the IDF, the prevalence of diabetes is the highest among the elderly population in Egypt, with 33.3% of people aged 65 and above living with the condition.

According to the Central Agency for Public Mobilization and Statistics (CAPMAS), Egypt's elderly population reached 6.5 million in 2019; of this, 3.5 million were males, while 3 million were females. The number has been increasing significantly since then and is expected to reach 10.5 million by 2030.

Growth in Investment in R&D and Promising Pipeline of Diabetes Drugs Fueling Market Expansion

Pharmaceutical companies have significantly increased their investments in R&D activities to create new and innovative diabetes drugs. These emerging drugs not only enhance the quality of life for people with diabetes but also work to reduce the risk of diabetes-related complications.

Growth in R&D investments has led to a wider array of treatment choices for diabetes, which is particularly vital because individuals with diabetes have diverse needs and responses to various medications.

Availability of treatment options empowers people with diabetes in Egypt to find a therapy that best suits their individual circumstances. Additionally, intense competition in the Egypt diabetes drugs market has contributed to a decrease in the cost of these medications. This cost reduction is making diabetes drugs more affordable and accessible for the people in Egypt.

Innovative diabetes drugs currently in the pipeline include insulin analogs, oral medications, and injectable drugs. Insulin analogs, for instance, are designed to be more efficient and convenient compared to traditional insulins, offering longer-lasting effects.

A range of novel oral medications is also being developed to enhance blood sugar control and reduce the risk of complications. Similarly, new injectable medications are under development with the goal of not only improving blood sugar control but also promoting weight loss.

Thus, increase in R&D investments and promising pipeline of diabetes drugs are bolstering the market trajectory, ultimately enhancing the overall care and well-being of people living with diabetes in the country.

High Incidence of Type 2 Diabetes

According to the diabetes drugs market analysis, the type 2 diabetes segment held significant share in 2022. Rise in prevalence of type 2 diabetes is anticipated to drive the segment during the forecast period.

Type 2 is the most prevalent type of diabetes and is characterized by the body’s inability to effectively utilize insulin. Some individuals can manage their blood glucose (blood sugar) levels through a healthy diet and regular exercise, while others may require medication or insulin to control their condition.

According to the data from the International Diabetes Federation, Egypt has more than eight million diabetes patients. The WHO estimates that around 30% of Egyptians suffer from hypertension, primarily due to excessive salt intake. Egypt was among the top 10 countries or territories with the highest estimated prevalence of diabetes in adults aged 20 to 79 in 2021.

Increase in Number of Retail Pharmacies

Based on distribution channel, the retail pharmacies segment accounted for the largest Egypt diabetes drugs market share in 2022. Retail pharmacies often have pharmacists who can educate patients. This ensures that individuals understand how to use drugs effectively and safely.

Retail pharmacies also offer convenience and accessibility to patients with diabetes. These pharmacies are commonly located in residential areas. Increase in number of retail pharmacies, easy availability of diabetes drugs in these settings, and growth in preference among patients for easy access to medication and advice from trained pharmacists are likely to boost the retail pharmacies segment during the forecast period.

Surge in Preference for Oral Antidiabetic Medications

Introduction of oral diabetes control drugs has marked a significant advancement in the pharmaceutical sector, offering diversified options for diabetes management. Currently, oral anti-diabetic medications encompass a broad spectrum, including metformin, sulfonylureas, DPP-4 inhibitors, and SGLT-2 inhibitors.

These drugs play a crucial role in regulating blood sugar levels and exhibit diverse mechanisms of action, providing healthcare professionals with a range of tools for tailored diabetes treatment. Convenience and effectiveness associated with these oral medications have contributed to the surging preference for oral delivery methods in diabetes care.

This shift toward oral anti-diabetic drugs highlights the industry's commitment to improve the accessibility and efficacy of diabetes management, ultimately improving the quality of life for individuals living with diabetes, while expanding the horizons of pharmaceutical innovation in this vital therapeutic area.

Analysis of Key Players in Egypt Diabetes Drugs Industry

The Egypt diabetes drugs landscape is consolidated, with the presence of small number of leading players. Expansion of product portfolio and mergers & acquisitions are key strategies implemented by the prominent players.

AstraZeneca, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, and Sanofi are some of the major players operating in the Egypt diabetes drugs market in Egypt.

Each of these companies have been summarized in the diabetes drugs market report based on parameters such as company overview, business strategies, financial overview, business segments, recent developments, and product portfolio.

Key Developments

• On March 08, 2023, Boehringer Ingelheim and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin), investigating a potential new indication to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes
• On December 15, 2021, Novo Nordisk, a leading global diabetes healthcare company, launched its latest innovation in diabetes medication in Egypt, with its once-weekly Ozempic for the treatment of type 2 diabetes
• In March 2020, Novo Nordisk announced the launch of ‘Ryzodeg,’ the latest innovation for management of diabetes in Egypt, in order to achieve a major change in diabetics’ lifestyle. Ryzodeg was approved by the U.S. Food and Drug Administration (FDA) in 2015 and the European Medicines Agency (EMA) in 2013. It is now commercially available in 31 countries. The new drug is a combination of insulin degludec and insulin aspart (IDegAsp) in one pen for the treatment of people with type 2 diabetes.
• In February 2020, the U.S. Food and Drug Administration (FDA) approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors. This decision makes Eli Lilly and Company's Trulicity the first and only type 2 diabetes medicine approved to reduce the risk of MACE for both primary and secondary prevention populations.

Egypt Diabetes Drugs Market Snapshot